|
Código del ensayo CO41942 |
|
Ensayo A phase ib/ii, open-label, multicenter study with a non-randomized stage evaluating the safety, pharmacokinetics, and efficacy of mosunetuzumab plus lenalidomide (+len) or glofitamab+len with or without obinutuzumab, and a randomized stage evaluating the safety, tolerability, and pharmacokinetics of sc versus iv mosunetuzumab+len in patients with relapsed or refractory follicular lymphoma |
|
Estado Abierto a inclusión |
|
Localización Tumoral Hematológicos |
|
Tipo de tumor Linfomas |
|
Tipo de ensayo Ensayo de Fase I |
|
Tipo de tratamiento Inmunoterapia |
|
Situación clínica |
|
Centro |
